Testing CTx001 for geographic atrophy (GA) in AMD
Part of Eyes & vision clinical trials.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have geographic atrophy (GA) in both eyes from age-related macular degeneration (AMD).
- Your eyesight and retinal details meet the study's specific measurements (like visual acuity, low-light vision, and retinal sensitivity).
- You have not had prior treatments for AMD or other eye conditions that could interfere with the study (e.g., wet AMD, certain surgeries, or complement inhibitor therapy).
- You are able to have regular eye imaging and follow the study procedures, and you meet age and reproductive health rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
This trial tests an investigational eye injection (RO7965032) for people with geographic atrophy, a form of dry age-related macular degeneration that causes progressive vision loss. The goal is to see if the treatment can slow further vision loss and preserve sight.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
Hear when a new Geographic Atrophy Secondary to Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.